34,701 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Purchased by Bender Robert & Associates

Bender Robert & Associates purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 34,701 shares of the company’s stock, valued at approximately $370,000. Bender Robert & Associates owned 0.15% of UroGen Pharma at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of URGN. Charles Schwab Investment Management Inc. grew its holdings in UroGen Pharma by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock valued at $996,000 after purchasing an additional 3,024 shares during the period. Oppenheimer & Co. Inc. acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $126,000. ARK Investment Management LLC grew its stake in shares of UroGen Pharma by 15.2% during the 4th quarter. ARK Investment Management LLC now owns 140,148 shares of the company’s stock valued at $1,493,000 after buying an additional 18,514 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock worth $1,001,000 after buying an additional 6,430 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of UroGen Pharma by 2.8% in the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock worth $546,000 after buying an additional 1,402 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

Insider Activity

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on URGN. HC Wainwright dropped their price target on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Monday. Finally, LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, UroGen Pharma has a consensus rating of “Buy” and an average target price of $38.20.

UroGen Pharma Stock Up 9.1 %

Shares of NASDAQ:URGN opened at $10.82 on Wednesday. UroGen Pharma Ltd. has a 12-month low of $9.03 and a 12-month high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The firm has a market cap of $253.77 million, a PE ratio of -3.43 and a beta of 1.12. The company has a fifty day simple moving average of $10.45 and a 200 day simple moving average of $11.70.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. On average, equities research analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.